Literature DB >> 30788666

Long-Term Follow-up in Patients with Spontaneous Intracerebral Hemorrhage Treated With or Without Surgical Intervention: a Large-Scale Retrospective Study.

XianXiu Chen1,2, Yuan-Chih Su3,4, Chun-Chung Chen3,5,6, Jeng-Hung Guo5, Chih-Ying Wu5,7, Sung-Tai Wei5, Der-Cherng Chen5, Jung-Ju Lin8, Shwn-Huey Shieh9, Cheng-Di Chiu10,11,12.   

Abstract

Debates regarding the most beneficial medical or surgical procedures for patients with spontaneous intracerebral hemorrhage (sICH) are still ongoing. We aimed to evaluate the risk of subsequent vascular disease and mortality in patients with sICH treated with and without surgical intervention, in a large-scale Asian population. Patients hospitalized within 2000 to 2013 who were newly diagnosed with sICH were identified using the National Health Insurance Research Database of Taiwan. Neuroendoscopy and craniotomy groups comprised patients who underwent surgical treatment within 1 week, while those in the control group did not undergo early surgical treatment. Outcomes included subsequent hemorrhagic and ischemic stroke, following acute myocardial infarction, congestive heart failure, and mortality. After propensity score matching, there were 663 patients in each group. Compared to that in the control group, the neuroendoscopy and craniotomy groups had a significantly higher risk of secondary vascular events at 1 to 3 months of follow-up (adjusted HR, 2.08 and 1.95; 95% CI, 1.21-3.58 and 1.13-3.35; p < 0.01 and p < 0.05, respectively), but a significantly lower risk after 3 years of follow-up (adjusted HR, 0.52 and 0.52; 95% CI, 0.35-0.78 and 0.35-0.77; p < 0.01 and p < 0.01, respectively). The mortality rate was higher in the craniotomy group at 6 to 12 months of follow-up (adjusted HR, 2.18; 95% CI, 1.06-4.49; p < 0.05) compared to that in the control group. Thus, a timely surgical intervention for hematoma evacuation is advantageous in preventing secondary vascular events and improving outcomes in the long term. However, greater attention to secondary ischemic stroke following the initial sICH episode is needed.

Entities:  

Keywords:  Spontaneous intracerebral hemorrhage; craniotomy; mortality; neuroendoscopy; stroke; subsequent vascular risk

Mesh:

Year:  2019        PMID: 30788666      PMCID: PMC6694356          DOI: 10.1007/s13311-019-00722-7

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  24 in total

1.  The STICH trial: what does it tell us and where do we go from here?

Authors:  Joseph P Broderick
Journal:  Stroke       Date:  2005-06-09       Impact factor: 7.914

2.  The accuracy of Medicare's hospital claims data: progress has been made, but problems remain.

Authors:  E S Fisher; F S Whaley; W M Krushat; D J Malenka; C Fleming; J A Baron; D C Hsia
Journal:  Am J Public Health       Date:  1992-02       Impact factor: 9.308

3.  The effects on prognosis of surgical treatment of hypertensive putaminal hematomas through transsylvian transinsular approach.

Authors:  R Alper Kaya; Osman Türkmenoğlu; Ibrahim M Ziyal; Türker Dalkiliç; Yüksel Sahin; Yunus Aydin
Journal:  Surg Neurol       Date:  2003-03

4.  Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial.

Authors:  A David Mendelow; Barbara A Gregson; Helen M Fernandes; Gordon D Murray; Graham M Teasdale; D Terence Hope; Abbas Karimi; M Donald M Shaw; David H Barer
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

5.  Initial multicenter technical experience with the Apollo device for minimally invasive intracerebral hematoma evacuation.

Authors:  Alejandro M Spiotta; David Fiorella; Jan Vargas; Alexander Khalessi; Dan Hoit; Adam Arthur; Jonathan Lena; Aquilla S Turk; M Imran Chaudry; Frederick Gutman; Raphael Davis; David A Chesler; Raymond D Turner
Journal:  Neurosurgery       Date:  2015-06       Impact factor: 4.654

6.  Site of bleeding and early outcome in primary intracerebral hemorrhage.

Authors:  A Arboix; E Comes; L García-Eroles; J Massons; M Oliveres; M Balcells; C Targa
Journal:  Acta Neurol Scand       Date:  2002-04       Impact factor: 3.209

Review 7.  Molecular pathophysiology of cerebral hemorrhage: secondary brain injury.

Authors:  Jaroslaw Aronowski; Xiurong Zhao
Journal:  Stroke       Date:  2011-04-28       Impact factor: 7.914

8.  Surgical treatment for large spontaneous basal ganglia hemorrhage: retrospective analysis of 253 cases.

Authors:  Q Li; C H Yang; J G Xu; H Li; C You
Journal:  Br J Neurosurg       Date:  2013-02-14       Impact factor: 1.596

9.  Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group.

Authors:  Joseph Broderick; Sander Connolly; Edward Feldmann; Daniel Hanley; Carlos Kase; Derk Krieger; Marc Mayberg; Lewis Morgenstern; Christopher S Ogilvy; Paul Vespa; Mario Zuccarello
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

10.  Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial.

Authors:  Daniel F Hanley; Richard E Thompson; John Muschelli; Michael Rosenblum; Nichol McBee; Karen Lane; Amanda J Bistran-Hall; Steven W Mayo; Penelope Keyl; Dheeraj Gandhi; Tim C Morgan; Natalie Ullman; W Andrew Mould; J Ricardo Carhuapoma; Carlos Kase; Wendy Ziai; Carol B Thompson; Gayane Yenokyan; Emily Huang; William C Broaddus; R Scott Graham; E Francois Aldrich; Robert Dodd; Cristanne Wijman; Jean-Louis Caron; Judy Huang; Paul Camarata; A David Mendelow; Barbara Gregson; Scott Janis; Paul Vespa; Neil Martin; Issam Awad; Mario Zuccarello
Journal:  Lancet Neurol       Date:  2016-10-11       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.